Organisation paid for research Program year 2025 Source: CMS Open Payments

CHI Health

Neither a doctor nor a teaching hospital

Research payments

$150,422

296 payments

Through program year 2025, CHI Health is reported as receiving $150,422 in research payments, across 296 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $13,181 3
2024 Research $20,645 5
2023 Research $30,091 7
2022 Research $56,394 56
2021 Research $22,154 224
2019 Research $7,957 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $79,543 11 payments
  2. Novo Nordisk AS $70,880 285 payments
Studies the money was for Research payments · program years 2019–2025
  1. Dapagliflozin in Acute Decompensated Heart Failure $71,586 10 payments
  2. Ex9536-4773 $53,498 130 payments
  3. Ex9536-4665 $15,831 106 payments
  4. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $7,957 1 payment
  5. Ex6018-4758 $1,550 49 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record